Large neutral amino acids supplementation in phenylketonuric patients

Journal of Inherited Metabolic Disease

Volumn 32, Issue 4, 2009, Pages 472-480

  Rocha, J C ^a   Martel, F ^b  

^a INSA ^*  (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HISTIDINE; ISOLEUCINE; LEUCINE; METHIONINE; NEOPHE; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PLACEBO; PREKUNIL; TETRAHYDROBIOPTERIN; THREONINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID BLOOD LEVEL; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; HUMAN; NEUROTOXICITY; PHENYLKETONURIA; PROTEIN DEGRADATION; PROTEIN DIET; REVIEW;

EID: 69449104991     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1132-x     Document Type: Review

References (76)

1. Berger V, Larondelle Y, Trouet A, Schneider YJ (2000) Transport mechanisms of the large neutral amino acid L-phenylalanine in the human intestinal epithelial caco-2 cell line. J Nutr 130: 2780-2788
2. Berry HK, Bofinger MK, Hunt MM, Phillips PJ, Guilfoile MB (1982) Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine. Pediatr Res 16:751-755. doi: 10.1203/ 00006450-198209000-00009
3. Bickel H, Gerrard J, Hickmans EM (1953) Influence of phenylalanine intake on phenylketonuria. Lancet 262:812-813. doi: 10.1016/ S0140-6736(53)90473-5
4. Binek-Singer P, Johnson TC (1982) The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. Biochem J 206:407-414
5. Blows WT (2000) Neurotransmitters of the brain: Serotonin, noradrenaline (norepinephrine), and dopamine. J Neurosci Nurs 32:234-238
6. Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677. doi: 10.1083/ jcb.40.3.648
7. Broer S (2008) Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 88:249-286. doi: 10.1152/physrev.00018.2006
8. Brumm VL, Azen C, Moats RA, et al (2004) Neuropsychological outcome of subjects participating in the PKU adult collaborative study: A preliminary review. J Inherit Metab Dis 27:549-566. doi: 10.1023/ B:BOLI.0000042985.02049.ff
9. Burgard P, Rey F, Rupp A, Abadie V, Rey J (1997) Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: Results of a cross-national and cross-sectional study. Pediatr Res 41:368-374. doi: 10.1203/00006450-199703000-00011
10. Burlina A, Blau N (2009) Effect of BH(4) supplementation on phenylalanine tolerance. J Inherit Metab Dis 32:40-45. doi: 10.1007/ s10545-008-0947-1
11. Burlina AB, Bonafe L, Ferrari V, Suppiej A, Zacchello F, Burlina AP (2000) Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis 23:313-316. doi: 10.1023/A:1005694122277
12. Centerwall SA, Centerwall WR (2000) The discovery of phenylketonuria: the story of a young couple, two retarded children, and a scientist. Pediatrics 105:89-103. doi: 10.1542/peds.105.1.89
13. Christensen HN (1953) Metabolism of amino acids and proteins. Annu Rev Biochem 22:233-260. doi: 10.1146/annurev.bi.22.070153.001313
14. del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of l -type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161-174. doi: 10.1016/j.ejps.2008.06.015
15. Dotremont H, Francois B, Diels M, Gillis P (1995) Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. J Inherit Metab Dis 18:127-130. doi: 10.1007/BF00711746
16. Fernstrom JD, Wurtman RJ (1972) Brain serotonin content: Physiological regulation by plasma neutral amino acids. Science 178:414-416. doi: 10.1126/science.178.4059.414
17. Finkelson L, Bailey I, Waisbren SE (2001) PKU adults and their return to diet: Predicting diet continuation and maintenance. J Inherit Metab Dis 24:515-516. doi: 10.1023/A:1010546000617
18. Fisch RO, Chang PN, Weisberg S, Guldberg P, Guttler F, Tsai MY (1995) Phenylketonuric patients decades after diet. J Inherit Metab Dis 18:347-353. doi: 10.1007/BF00710427
19. Griffiths P, Paterson L, Harvie A (1995) Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. J Intellect Disabil Res 39(Pt 5): 365-372
20. Guttler F, Lou H (1986) Dietary problems of phenylketonuria: Effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9 (Supplement 2):169-177. doi: 10.1007/BF01799701
21. Hanley WB (2004) Adult phenylketonuria. Am J Med 117:590-595. doi: 10.1016/j.amjmed.2004.03.042
22. Hawkins RA, O'Kane RL, Simpson IA, Vina JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136:218S-226S
23. Hidalgo IJ, Borchardt RT (1990) Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys Acta 1028:25-30. doi: 10.1016/0005-2736(90)90261-L
24. Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ (2009) Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab 96(4):177-182. Epub 2009 Feb 6
25. Huether G, Neuhoff V, Kaus R (1983) Brain development in experimental hyperphenylalaninaemia: Disturbed proliferation and reduced cell numbers in the cerebellum. Neuropediatrics 14:12-19. doi: 10.1055/s-2008-1059547
26. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629-23632. doi: 10.1074/jbc.273.37.23629
27. Karasov W, Solberg D, Carter S, et al (1986) Uptake pathways for amino acids in mouse intestine. Am J Physiol 251:G501-508
28. Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H (1995) Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis 18:653-664. doi: 10.1007/BF02436753
29. Koch R, Guttler F (2000) Benefits of mutation analysis and examination of brain phenylalanine levels in the management of phenylketonuria. Pediatrics 106:1136. doi: 10.1542/peds.106.5.1136
30. Koch R, Moats R, Guttler F, Guldberg P, Nelson M Jr (2000) Blood-brain phenylalanine relationships in persons with phenylketonuria. Pediatrics 106:1093-1096.doi: 10.1542/peds.106.5.1093
31. Koch R, Moseley KD, Yano S, Nelson M Jr, Moats RA (2003) Large neutral amino acid therapy and phenylketonuria: A promising approach to treatment. Mol Genet Metab 79:110-113. doi: 10.1016/S1096-7192(03)00078-7
32. Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C (1995) Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1 H magnetic-resonance spectroscopy. J Magn Reson B 107:242-251. doi: 10.1006/jmrb.1995.1084
33. Kure S, Hou DC, Ohura T, et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135:375-378. doi: 10.1016/S0022-3476(99)70138-1
34. Lee P, Treacy EP, Crombez E, et al (2008) Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A 146A:2851-2859. doi: 10.1002/ ajmg.a.32562
35. Levy H, Burton B, Cederbaum S, Scriver C (2007) Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH 4) in phenylketonuria and its use in treatment. Mol Genet Metab 92:287-291. doi: 10.1016/j.ymgme.2007.09.017
36. Lou HC, Toft PB, Andresen J, et al (1994) Unchanged MRI of myelin in adolescents with PKU supplied with non-phe essential amino acids after dietary relaxation. Acta Paediatr 83:1312-1314. doi: 10.1111/ j.1651-2227.1994.tb13025.x
37. Mastroberardino L, Spindler B, Pfeiffer R, et al (1998) Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395:288-291. doi: 10.1038/26246
38. Matalon KM (2001) Developments in phenylketonuria. Top Clin Nutr 16:41-50
39. Matalon R, Michals-Matalon K, Bhatia G, et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 29:732-738. doi: 10.1007/s10545-006-0395-8
40. Matalon R, Michals-Matalon K, Bhatia G, et al (2007) Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis 30:153-158. doi: 10.1007/s10545-007-0556-4
41. McKean CM (1972) The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res 47:469-476. doi: 10.1016/0006-8993(72)90653-1
42. McKean CM, Boggs DE, Peterson NA (1968) The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain. J Neurochem 15:235-241. doi: 10.1111/ j.1471-4159.1968.tb06202.x
43. Moats RA, Koch R, Moseley K, et al (2000) Brain phenylalanine concentration in the management of adults with phenylketonuria. J Inherit Metab Dis 23:7-14. doi: 10.1023/A:1005638627604
44. Moats RA, Moseley KD, Koch R, Nelson M Jr (2003) Brain phenylalanine concentrations in phenylketonuria: Research and treatment of adults. Pediatrics 112:1575-1579
45. Moller HE, Ullrich K, Weglage J (2000) In vivo proton magnetic resonance spectroscopy in phenylketonuria. Eur J Pediatr 159(Supplement 2):S121-125. doi: 10.1007/PL00014374
46. Munck BG, Munck LK (1994) Phenylalanine transport in rabbit small intestine. J Physiol 480(Pt 1):99-107
47. Ney DM, Gleason ST, van Calcar SC, et al (2009) Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 32:32-39. doi: 10.1007/s10545-008-0952-4
48. Novotny EJ Jr, Avison MJ, Herschkowitz N, et al (1995) In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy. Pediatr Res 37:244-249. doi: 10.1203/ 00006450-199502000-00020
49. + -dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. Am J Physiol Endocrinol Metab 285:E1167-1173
50. + -dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: Mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab 287:E622-629. doi: 10.1152/ajpendo.00187.2004
51. Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758. doi: 10.1007/s11095-007-9374-5
52. Pardridge WM (1998) Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 23:635-644. doi: 10.1023/ A:1022482604276
53. 1H magnetic resonance spectroscopy. Pediatr Res 38:657-663. doi: 10.1203/00006450-199511000-00005
54. Pietz J, Dunckelmann R, Rupp A, et al (1998) Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr 157:824-830. doi: 10.1007/s004310050945
55. Pietz J, Kreis R, Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103:1169-1178. doi: 10.1172/JCI5017
56. Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V (2000) Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport 11:1361-1364. doi: 10.1097/ 00001756-200004270-00042
57. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N (1994) Early-treated phenylketonuria: Adult neuropsychologic outcome. J Pediatr 124:388-392. doi: 10.1016/S0022-3476(94)70360-4
58. Rocha JC, Vilarinho L, Cabral A, Vaz Osório R, de Almeida MF (2007) Consensus for the nutritional treatment of phenylketonuria. Acta Pediatr Port 38:44-54
59. Sanchez del Pino MM, Hawkins RA, Peterson DR (1992) Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. J Biol Chem 267:25951-25957
60. Sanchez del Pino MM, Peterson DR, Hawkins RA (1995) Neutral amino acid transport characterization of isolated luminal and abluminal membranes of the blood-brain barrier. J Biol Chem 270:14913-14918. doi: 10.1074/ jbc.270.25.14913
61. Sarkissian CN, Gámez A, Scriver CR (2009) What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis 32(1):3-9.Epub 2008 Aug 3
62. Schindeler S, Ghosh-Jerath S, Thompson S, et al (2007) The effects of large neutral amino acid supplements in PKU: An MRS and neuropsychological study. Mol Genet Metab 91:48-54. doi: 10.1016/ j.ymgme.2007.02.002
63. Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L (1994) Sustained attention in adult phenylketonuria: The influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 16:681-688. doi: 10.1080/01688639408402681
64. Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667-1724
65. Smith QR (2000) Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 130:1016S-1022S
66. Stevens BR, Ross HJ, Wright EM (1982) Multiple transport pathways for neutral amino acids in rabbit jejunal brush border vesicles. J Membr Biol 66:213-225. doi: 10.1007/BF01868496
67. Surtees R, Blau N (2000) The neurochemistry of phenylketonuria. Eur J Pediatr. 159(Supplement 2):S109-113. doi: 10.1007/PL00014370
68. Thompson AJ, Smith I, Brenton D, et al (1990) Neurological deterioration in young adults with phenylketonuria. Lancet 336:602-605. doi: 10.1016/ 0140-6736(90)93401-A
69. van Calcar SC, MacLeod EL, Gleason ST, et al (2009) Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 89(4):1068-1077. Epub 2009 Feb 25
70. van Meer G, Simons K (1986) The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J5: 1455-1464
71. van Meer G, Gumbiner B, Simons K (1986) The tight junction does not allow lipid molecules to diffuse from one epithelial cell to the next. Nature 322:639-641. doi: 10.1038/322639a0
72. van Spronsen FJ, Hoeksma M, Reijngoud DJ (2009) Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 32:46-51. doi: 10.1007/s10545-008-0946-2
73. Walter JH, White FJ, Hall SK, et al (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360:55-57. doi: 10.1016/S0140-6736(02)09334-0
74. Walter JH, Lee PJ, Burgard P (2006) Hyperphenylalaninaemia. In Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases. Heidelberg: Springer, 221-232
75. Weglage J, Wiedermann D, Denecke J, et al (2001) Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol 50:463-467. doi: 10.1002/ana.1226
76. Weglage J, Wiedermann D, Denecke J, et al (2002) Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria. J Inherit Metab Dis 25:431-436. doi: 10.1023/ A:1021234730512